A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells
Kunlong Zhang, et al.
Introduction Acute myeloid leukemia (AML) is an aggressive hematopoietic cancer characterized by blocked differentiation of myeloid lineage [1–3]. Due to risk stratification-directed therapy, treatment outcomes with a 5-year survival rates…